Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using “Neo-Islets,” aggregates of adipose stem and pancreatic islet cells (INAD 012-776)

Anna Gooch¹, Ping Zhang¹, Zhuma Hu¹, Natasha Loy Son², Nicole Avila², Julie Fischer², Gregory Roberts³, Rance Sellon³, Christof Westenfelder¹,4*

¹ SymbioCellTech, LLC, Salt Lake City, Utah, United States of America, ² Veterinary Specialty Hospital, San Diego, California, United States of America, ³ Department of Veterinary Clinical Sciences, Washington State University, Pullman, Washington, United States of America, ⁴ Department of Medicine, Division of Nephrology, University of Utah, Salt Lake City, Utah, United States of America

* christof.westenfelder@hsc.utah.edu

Abstract

We previously reported that allogeneic, intraperitoneally administered “Neo-Islets,” composed of cultured pancreatic islet cells co-aggregated with high numbers of immunoprotective and cytoprotective Adipose-derived Stem Cells, reestablished, through omental engraftment, redifferentiation and splenic and omental up-regulation of regulatory T-cells, normoglycemia in autoimmune Type-1 Diabetic Non-Obese Diabetic (NOD) mice without the use of immunosuppressive agents or encapsulation devices. Based on these observations, we are currently testing this Neo-Islet technology in an FDA guided pilot study (INAD 012–776) in insulin-dependent, spontaneously diabetic pet dogs by ultrasound-guided, intraperitoneal administration of 2x10e5 Neo-Islets/kilogram body weight to metabolically controlled (blood glucose, triglycerides, thyroid and adrenal functions) and sedated animals. We report here interim observations on the first 4 canine Neo-Islet-treated, insulin-dependent pet dogs that are now in the early to intermediate-term follow-up phase of the planned 3 year study (>6 months post treatment). Current results from this translational study indicate that in dogs, Neo-Islets appear to engraft, redifferentiate and physiologically produce insulin, and are rejected by neither auto- nor allo-immune responses, as evidenced by (a) an absent IgG response to the allogeneic cells contained in the administered Neo-Islets, and (b) progressively improved glycemic control that achieves up to a 50% reduction in daily insulin needs paralleled by a statistically significant decrease in serum glucose concentrations. This is accomplished without the use of anti-rejection drugs or encapsulation devices. No adverse or serious adverse events related to the Neo-Islet administration have been observed to date. We conclude that this minimally invasive therapy has significant translational relevance to veterinary and clinical Type 1 diabetes mellitus by achieving complete and at this point partial glycemic control in two species, i.e., diabetic mice and dogs, respectively.
Introduction

Diabetes mellitus (DM) is a common endocrine disorder in dogs, and it is estimated that there are currently 700,000 insulin-dependent pet dogs with DM in the US [1–4]. Their care is burdensome and expensive for their owners. As in humans, Type 1 (T1DM) in dogs is generally irreversible, and is caused by lack of insulin secretion in response to glucose, resulting in hyperglycemia, acid-base and electrolyte disorders, polydipsia, polyuria and weight loss, and is accompanied by a broad spectrum of diabetes-induced end organ damage and other complications, including blindness due to retinopathy and cataracts, opportunistic infections, neurological and other serious micro- and macro-vascular complications [4–6]. Although dogs were the model in which insulin was originally discovered, and remain a major large animal model for the refinement of diabetic treatments such as pancreas and islet cell transplants, almost no advances in the treatment of diabetic dogs have been made in the last 50 years [7]. A few studies have examined xeno- or allogeneic islet transplantation to reverse or ameliorate DM in dogs and have had varying degrees of success. Yet, insulin replacement therapy and blood glucose monitoring remain the only currently available therapy for these animals [7–9]. Due to the challenges of medically managing a diabetic dog, up to 40% of owners opt to euthanize their dogs within a day of diagnosis rather than treat them [1,10].

While the pathogenic mechanisms of canine T1DM are still incompletely understood, there is evidence that autoimmune injury of pancreatic beta cells plays a role in approximately 1/3 of cases [3,4,7,10–12]. T1DM occurs with equal frequency in male and female neutered dogs, but as with Non-Obese Diabetic (NOD) mice, at higher frequency in intact females vs. males, suggesting a role for female hormones in the development of the disease in dogs [1,3,13–15]. While T1DM affects both juvenile and adult dogs [1,3,7], it is more commonly seen in adults, generally diagnosed between the ages of 3 and 15 years [3,10]. Some groups have reported isolation of auto-antibodies to proinsulin, GAD65 and IA-2 from the sera of diabetic animals [16,17]. Others, however, have been unable to confirm the presence of such auto-antibodies in the same, previously tested sera, or in sera from other diabetic dogs [2,14]. On the other hand, several studies have found a genetic association between certain dog leukocyte antigen alleles (DLA) and the development of DM in dogs, similar to that found between HLA alleles and the development of DM in humans [12,18,19]. Despite some controversy as to the contribution of immune-mediated destruction of beta cells to canine DM, all pioneering work on islet and pancreas transplantation for humans was carried out in dogs and clearly demonstrated the need for immunosuppression or immune-isolation, as well as sufficient nutrition/oxygenation and vascularization for islet allo-graft survival [7,20].

Dog survival time post the diagnosis of diabetes is short [1,10]. In one study, median post-diagnosis survival time was only 57 days, due either to pet owners’ unwillingness to care for a diabetic animal, or to the dog suffering from advanced stages of diabetic complications at the time of diagnosis. For dogs surviving beyond the first day after diagnosis, the median survival time was 2 years [1]. These low survival rates, and clear unwillingness of some owners to care for diabetic animals, underscore the need for novel and effective therapeutics that remove much of the burden of diabetes treatment and maintenance from pet owners, and to facilitate the survival of affected dogs.

We previously demonstrated that allogeneic, intraperitoneally (i.p.) administered “Neo-Islets” (NIs), composed of culture expanded islet cells (ICs) that have undergone partial Epithelial-Mesenchymal transition, co-aggregated with high numbers of immunoprotective and cytoprotective Adipose-derived Stem Cells (ASCs), could reestablish normoglycemia in NOD mice with autoimmune T1DM without the use of encapsulation devices or immunosuppressive agents [21]. Glycemic control was similarly achieved using dog-derived ASCs and ICs in a
Streptozotocin (STZ) model of diabetes in NOD/SCID mice [21]. Dose finding studies in this model indicated that 2x10e5 canine Neo-Islets (cNIs) per kg body weight (b.wt.) given i.p. would be sufficient to control blood glucose levels [21].

Based on these studies, we initiated an FDA-CVM guided pilot study (INAD 012–776) to assess the (i) safety, (ii) feasibility and (iii) efficacy of allogeneic cNIs in significantly reducing or eliminating the need for exogenous insulin in spontaneously diabetic, insulin-dependent pet dogs. We further assessed whether the administered cNIs elicited an allo-immune response. This pilot study is currently ongoing at Veterinary Specialty Hospital in San Diego, CA, and at the Veterinary Teaching Hospital, Washington State University in Pullman, WA. In this translational study, six dogs have been treated and four followed for more than 6 months. We report here on the course of the first four cNI treated dogs that have been followed for more than 6 months. The overall rationale of demonstrating that this cNI therapy is also effective in a second, larger diabetic mammal, the dog, is the fact that this will further strengthen the justification for the currently planned conduct of a clinical trial in human study subjects with T1DM.

Materials and methods

Reagents

Reagents used and their manufacturers are listed as indicated below, except for PCR reagents and primers which are listed in S1 Table.

Study design

An FDA guided pilot study (INAD 012–776) was developed with IACUC approval at (a) Washington State University in Pullman, WA (WSU) and (b) the Veterinary Specialty Hospital in San Diego, CA (VSH). The overall study goal is to include ten insulin dependent pet dogs and follow them for three years post-cNI infusion. Seven dogs have been enrolled according to the criteria in Table 1. Informed consent was obtained from all dog owners prior to enrollment. One owner withdrew her dog prior to treatment, 6 dogs have been treated, and 4

Table 1. Enrollment criteria.

| Enrollment Criteria | Insulin dependent, diabetic dog on established insulin and diet regimen  
Weight between 5 and 12 kg  
Spayed if female  
Ability of the dogs’ owners to follow the study protocol, requiring close monitoring of blood glucose concentrations, recording of insulin dosing, body weights and other daily activities. |
|---------------------|------------------------------------------------------------------------|
| Exclusion Criteria  | History of malignancy  
Significant illness unrelated to the diabetic state such that the PI believes the dog to be a poor candidate  
Significantly advanced age such that the PI believes the dog to be a poor candidate  
Contraindication to utilized sedatives and other drugs  
Participation in another, ongoing clinical trial |
| These specific diabetes-associated complications are documented, but do not constitute Exclusion Criteria | Presence of:  
End-organ damage  
Cataracts  
Neuropathy  
Renal disease  
History of pancreatitis |

https://doi.org/10.1371/journal.pone.0218688.t001
of those (VSH-01, VSH-02, WSU-01 and WSU-02) have been followed for 6 months or longer. Enrolled dogs’ demographics are shown in Table 2 and comorbidities in Table 3. The four dogs discussed in this manuscript were screened and are being followed as shown in S2 Table. It should be noted that although no treated dog is currently 3 years post cNI infusion, this table summarizes the entire follow-up plan as approved for this pilot study by the FDA and IACUC. Pre-treatment serum samples from treated dogs were tested for the presence of islet autoantibodies (see below for details), and all dogs were examined for comorbidities. Prior to treatment, blood glucose, triglycerides and other important metabolic factors (thyroid, pancreas, and adrenal function) were assessed and treated as necessary. After blood glucose and triglyceride levels were adequately controlled (stable blood glucose levels \( \leq 350 \); fasting triglycerides between 20–300 mg/dL), 2x10\(^{5}\) allogeneic cNIs per kg b.wt. were given i.p.. In all animals, blood glucose and fructosamine concentrations, insulin requirements, body weights, food and fluid intake, formation of antibodies to allogeneic cNIs, animal activity and the development of adverse events were closely monitored by the owners, PIs and the primary veterinarians for each dog.

Table 2. Demographics of enrolled study subjects.

| Dog #  | Treated | Sex | Breed             | Weight\(^{+}\) (kg) | Age\(^{-}\) (yrs) | Yrs of DM\(^{**}\) | Insulin dose\(^{+}\) |
|--------|---------|-----|-------------------|---------------------|------------------|-------------------|---------------------|
| VSH-01 | yes     | M   | French Bulldog    | 12.3                | 9                | 2.5               | 4.5–5.5 U Novolin BID |
| VSH-02 | yes     | M   | Bichon Mix        | 6.9                 | 7                | 0.5               | 5 U Vetsulin BID     |
| VSH-03 | yes     | F   | Bichon Poodle Mix | 5.8                 | 11               | 2                 | 7.5 U Vetsulin BID   |
| VSH-04 | yes     | M   | Chihuahua Mix     | 7.3                 | 12               | 1                 | 9 U Vetsulin BID     |
| VSH-05 | withdrawn | M | Chihuahua Mix     | 7                   | 7                | 1                 | 6 U Vetsulin BID     |
| WSU-01 | yes     | F   | American Eskimo   | 11                  | 1.8              | 0.8               | 2.5 U Vetsulin BID   |
| WSU-02 | yes     | M   | Chihuahua Mix     | 7                   | 1                | 0.5               | 4 U Vetsulin BID     |

Abbreviations: U = Units, WSU = Washington State University, VSH = Veterinary Specialty Hospital, BID = twice per day. Insulin is listed as per dose. The total daily dose is double that given in the table.

*, at enrollment
**, at time of treatment

https://doi.org/10.1371/journal.pone.0218688.t002

of those (VSH-01, VSH-02, WSU-01 and WSU-02) have been followed for 6 months or longer. Enrolled dogs’ demographics are shown in Table 2 and comorbidities in Table 3. The four dogs discussed in this manuscript were screened and are being followed as shown in S2 Table. It should be noted that although no treated dog is currently 3 years post cNI infusion, this table summarizes the entire follow-up plan as approved for this pilot study by the FDA and IACUC. Pre-treatment serum samples from treated dogs were tested for the presence of islet autoantibodies (see below for details), and all dogs were examined for comorbidities. Prior to treatment, blood glucose, triglycerides and other important metabolic factors (thyroid, pancreas, and adrenal function) were assessed and treated as necessary. After blood glucose and triglyceride levels were adequately controlled (stable blood glucose levels \( \leq 350 \); fasting triglycerides between 20–300 mg/dL), 2x10\(^{5}\) allogeneic cNIs per kg b.wt. were given i.p.. In all animals, blood glucose and fructosamine concentrations, insulin requirements, body weights, food and fluid intake, formation of antibodies to allogeneic cNIs, animal activity and the development of adverse events were closely monitored by the owners, PIs and the primary veterinarians for each dog.

Table 3. Clinical pretreatment data on dogs that are \( \geq \) 6 months post-cNI treatment.

| Dog #  | Sex | Breed             | Cataracts; moderate adrenomegaly, mild renal degenerative changes | HbA1c pretreatment, 6.9% | Fructosamine pretreatment, 366 μmol/L | VSH-01   | Male, neutered (DOB 8/8/08) |
|--------|-----|-------------------|---------------------------------------------------------------|-------------------------|----------------------------------------|----------|-----------------------------|
|        |     |                   |                                                               |                         |                                        |          | No history of pancreatitis, but evidence on screening abdominal ultrasound (US) of suspected chronic or previous pancreatitis |
|        |     |                   |                                                               |                         |                                        |          | Cataracts; moderate adrenomegaly, mild renal degenerative changes |
|        |     |                   |                                                               |                         |                                        |          | HbA1c pretreatment, 6.9% |
|        |     |                   |                                                               |                         |                                        |          | Fructosamine pretreatment, 366 μmol/L |
| WSU-01 | Female, spayed (DOB 6/15/16) | No history nor evidence of pancreatitis | History of liver disease | HbA1c pretreatment, 7.7% | Fructosamine pretreatment, 301 μmol/L | WSU-01   | Male, neutered (DOB 3/28/11) |
|        |     |                   |                                                               |                         |                                        |          | No history of pancreatitis, but evidence on screening abdominal US of suspected chronic or previous pancreatitis |
|        |     |                   |                                                               |                         |                                        |          | Hypothyroid (on 0.1 mg Synthroid BID), diagnosed through screening; mild renal degenerative changes |
|        |     |                   |                                                               |                         |                                        |          | HbA1c pretreatment, 12.1% |
|        |     |                   |                                                               |                         |                                        |          | Fructosamine pretreatment, 439 μmol/L |
| WSU-02 | Male, neutered (DOB 4/15/17) | No history nor evidence of pancreatitis | History of liver disease | HbA1c pretreatment, 8.4 | Fructosamine pretreatment, 281 μmol/L | WSU-02   | Male, neutered (DOB 4/15/17) |

https://doi.org/10.1371/journal.pone.0218688.t003
**Blood glucose levels**

After infusion of cNIs, blood glucose concentrations were assessed by the owner at least twice daily (morning and evening) using an **AlphaTrak** glucometer or continuously monitored using a **FreeStyle Libre** glucometer in order to guide insulin administration. Insulin (Vetsulin or Novolin) was administered s.c. BID based on blood glucose readings, and the doses given were recorded by the owner and reported to the PI.

**Cells**

**Cell donor information.** All cells, ASCs and ICs, for the study were obtained through an NIH sharing agreement from 27 dogs being euthanized under a University of Utah IACUC approved protocol. This study involved no use of test agents, but did involve the use of a surgically implanted pacemaker in some dogs to induce heart failure, as well as the use of resynchronization therapy via the pacemaker as an experimental treatment. Dogs were up-to-date on vaccinations at the time of euthanasia.

**Islets and ASCs.** Islets and ASCs were isolated and cultured from dogs as previously reported [21–26], and as described in detail in the Supporting Information section of our previous publication [21]. Prior to cNI formation, cultured ASCs were characterized for their ability to undergo trilineage (adipo-, osteo-, chondrogenic) differentiation as described [21] and for surface marker expression of CD90, CD44, CD34, CD45 and DLA-DR as in our previous publication [27], and using the following antibodies: phycoerythrin (PE)-labeled, monoclonal, rat anti-dog CD90 IgG2b, and isotype control (Invitrogen, 12–5900 and 12–4031-83); allophycocyanin (APC)-labeled, monoclonal, mouse anti-dog CD44 IgG1, and isotype control (R&D, FABS449A and IC002A); PE-labeled, monoclonal, mouse anti-dog CD34 IgG1, and isotype control (BD Biosciences 559369 and 554680); R-PE-labeled, monoclonal, rat anti-dog CD45 IgG2b, and isotype control (BioRad MCA1042PE and PA5-33195), PE-labeled, monoclonal, mouse anti-human HLA-DR IgG2a (cross-reacts with dog), and isotype control (BD Biosciences 555812 and 555574). All antibodies were used at the concentrations recommended by their respective manufacturers. Prior to use, culture expanded cell lines (ASCs and ICs) were karyotyped by an independent laboratory and found to be normal (Laboratory of Molecular Cytogenetics and Genomics, Veterinary Medicine and Biomedical Sciences, Texas A & M University, College Station, Texas).

**Cell banking.** Passage 0 (P0) cultured islet cells and P2 ASCs were suspended in CryoStor CS10 (BioLife Solutions, 210102) and banked, frozen in liquid nitrogen (-140˚C) until ready for final expansion and cNI formation. Prior to freezing, cells were release tested for viability, sterility, endotoxin, *Mycoplasma*, expression of various genes involved in immune modulation, cell survival and angiogenesis (see **S1 Table**), and dog-specific adventitious agents (see **Table 4**).

**Real time PCR (rtPCR)**

rtPCR was carried out as described in our previous publication [21] using the reagents and primers listed in **S1 Table**. In brief, Relative Quantification, (RQ; defined as is standard as $2^{-\Delta\Delta CT}$ where CT is the Cycle Threshold [28]), was calculated through normalization to internal (deltaCT; beta actin and beta 2 microglobulin) and external controls (delta-deltaCT; parent cells), both accomplished using the ABS 7500 Real Time PCR System and software. Results are presented as log10(RQ) = log10(RQmin and RQmax) so that up- and down- gene regulation is represented equally [29]. Differences between expression levels greater than log10(RQ) 2 or log10 (RQ) -2 were considered significant [29].
Final product (cNI) formation and storage
cNIs were formed in ultra-low adherent 10-layer Cell Stacks (Corning, custom made product) from freshly cultured banked ICs and ASCs using 70x10^6 cells per layer and 140 ml of DMEM (Gibco 11885–084) + 10% dog serum (Golden West) as described in our previous publication [21]. cNIs were harvested and resuspended in 50 to 100 ml of sterile Plasmalyte A (Baxter, 2B2543) + 2% HEPES (Gibco), pH 7.4 at a concentration of 2x10^7 clustered cells/ml, and placed in a sterile 100 ml syringe (Wilburn Medical, WUSA/100). The final product was release tested (viability, sterility, endotoxin, Mycoplasma, gram stain, gene expression of insulin (INS), glucagon (GCG), somatostatin (SST), pancreatic polypeptide (PPY), pancreatic and duodenal homeobox 1 (PDX1), vascular endothelial growth factor A (VEGFa), stromal cell derived factor 1 (CXCL12), and stored and transported to the study site at 4˚C for administration within 48 hrs of packaging.

Cell bank and final product release testing
Cell viability was assessed using fluorescein diacetate (Sigma, F7378) and propidium iodide (Life Technologies P3566) as per the manufacturers’ instructions. Sterility was assessed as described in 21 CFR 610.12, using Tryptic Soy Broth (Sigma, 22092) and Fluid Thioglycollate Medium (Sigma, T9032) and following the manufacturer’s instructions. Endotoxin levels were determined using the Charles River Endosafe Nexgen PTS system and reagents (Charles River) following the manufacturer’s instructions. Possible Mycoplasma contamination was assessed using the MycoAlert PLUS Mycoplasma Detection Kit (Lonza, LT07-701 and LT07-518) per the manufacturer’s instructions. Samples of banked cells from each donor dog were sent to Zoologix for relevant adventitious agent testing. Prior to cNI formation, ASCs were assessed for expression of genes involved in immune modulation, cell survival and angiogenesis (see S1 Table). ICs were analyzed for expression of islet hormone associated genes. Gram staining was conducted by standard methods using a kit (Sigma, 77730-1KT-F). Cell and cNI release criteria are listed in Table 4.

Testing of treated dogs’ sera for antibodies to Islet Cells and ASCs
Prior to and at ~6 weeks post cNI treatment, 1 ml of serum was collected from each study dog. 5x10^4 banked allogeneic ASCs, and (separately) 5x10^4 banked allogeneic ICs were incubated for 30 min at room temperature with 100 uL serum each. Cells were then centrifuged at 600 x g.

Adventitious agents tested:
Neorickettsia risticii, Mycoplasma haemocanis, Mycoplasma canis, Bartonella henselae, B. bacilliformis, B. clarridgeiae, B. elizabethae, B. quintana and B. vinsonii subsp. Berkoffii, Brucella abortus, B. microti, B. melitensis, B. pinnipedialis, B. suis, B. canis, B. ovis and B. neotomae, Neorickettsia helmintheca, Cryptococcus neoformans, Influenza A H5N1, H5N2, H1N1, H2N2, H3N8, H4N6, H7N7, H8N4 and H9N2, canine herpesvirus, Toxoplasma gondii

https://doi.org/10.1371/journal.pone.0218688.t004

| Table 4. Release criteria for cells and Neo-Islets. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Viability | Sterility | Endotoxin | Mycoplasma | Adventitious Agents | Gene Expression (rtPCR) | Extracellular Marker (FACS; % positive) |
| ASCs | ≥ 70% | No growth after 14 days | < 5.0 EU/ml | B/A <1.2 | negative for all tested | Significant increase in Ido expression upon overnight culture with 10 ng/ml INF-γ | ≥ 90% CD90 and CD44 ≤ 4% CD34, CD45, and DLA-DR |
| Islet Cells | ≥ 70% | No growth after 14 days | < 5.0 EU/ml | B/A <1.2 | negative for all tested | + Ins | NA |
| Neo-Islets | ≥ 70% | negative Gram stain; no growth after 14 days | < 5.0 EU/ml | B/A <1.2 | NA | + Ins | NA |
g for 5 min; the supernatant was removed and the cell pellets resuspended in 200 uL Phosphate Buffered Saline (PBS, Sigma, 11666789001) +1% Fetal Bovine Serum (FBS, GEHealthcare, SH30910.03). Cells were then incubated at room temperature for 30 min with a 1:200 dilution of FITC-labeled, polyclonal rabbit anti-dog IgG or isotype control (Jackson ImmunoResearch; 304-095-003, lot #13971 and 011-090-003, lot #127025 respectively). They were then centrifuged, washed once with PBS + 1% FBS; resuspended in 400 uL PBS + 1% FBS, and analyzed by FACS as previously described [21].

Enzyme linked immunosorbent assays (ELISAs)

ELISAs for GAD65 and IA2 autoantibodies were kindly carried out by Dr. Boris Fehse, University of Hamburg, Germany, using GAD65 and IA2 ELISA kits (both from Euroimmun, Lübeck, Germany, EA 1022–9601 G and EA 1023–9601 G, respectively) and the same serum samples were analyzed for allo-antibody levels. The GAD65 kit has previously been shown to cross-react with dog antibodies [30].

cNI Administration

cNIs were administered to dogs by the site’s veterinary ultrasonographer and PI as follows: an i.v. catheter was placed, and the dog was sedated with dexmedetomidine (5 mcg/kg) and butorphanol (0.1–0.2 mg/kg). Abdominal fur was shaved, and skin was prepared for aseptic injection. NIs were warmed to room temperature, and an 18 gauge, sterile cannula was placed through the linea alba, ~ 3–4 cm cranial to the umbilicus, under ultrasound guidance to intra-peritoneally infuse normal saline test solution, then the suspended cNIs over a 2–3 minute period. Once the administrations were completed, the cannula was withdrawn. Ultrasound imaging was carried out to check for abdominal bleeding. Sedation was reversed with atipamezole (Antisedan), and the dog was monitored until determined stable by the PI and veterinary staff. Dogs returned home with their owners the same day once the PI determined that they were stable and ready. Owners were advised that the dogs’ serum glucose concentrations should be kept ≤ 210 mg/dL to protect the graft cells and facilitate redifferentiation into insulin producing cells.

Planned follow-up schedule per full protocol (note, no dog is yet fully 3 years post-treatment)

Month 1. Dog owners check and record their dog’s blood glucose levels every 12 hours, and record food and water intakes and weights once per week on supplied forms. Dog owners administer insulin to dogs as needed and as instructed by the PI. Dogs are brought in for a physical examination and laboratory studies as indicated in S2 Table.

Months 2–12. Dog owners continue to check and record their dog’s blood glucose levels twice per day; record dogs’ daily food and water intakes and weights every other week on supplied forms and electronically through month 6, and then as deemed necessary by the PI. Dog owners are responsible for the continued administration of insulin to dogs as needed and as instructed by the PI. Dogs are brought in for a physical examination once per month post treatment through month 6, and once per quarter in months 6–12. Fructosamine levels, a chemistry panel and urinalysis are obtained at the 3rd and 6th month visits. At the 6 months visit, a CBC, Serum chemistry and electrolyte panel, HbA1c, and urine are collected. At each visit, potential changes in the degree of preexisting end-organ damage are carefully documented.

Years 1–3. Dog owners are responsible for continued checking of blood glucose levels and administering insulin as prescribed by the PI. Dogs are brought in for a physical
examination once per quarter through the 36th month post treatment, to assess changes in the
degree of documented end-organ damage. Fructosamine levels, HbA1c and chemistry panels
are checked at each visit. Once per year, a CBC and a urinalysis are obtained.

Statistical analysis
Unless otherwise indicated, data are expressed as mean ± SEM or mean ± 95% confidence
interval, as indicated. Primary data were collected using Excel (Microsoft, Redmond, WA),
and statistical analyses were carried our using Prism (GraphPad, San Diego, CA). Two tailed t-
tests were used to assess differences between data means. A P value of < 0.05 was considered
significant. For rtPCR, data are presented as Log10RQ, and statistical significance is defined as
≥ ± 2, as described in [29].

Results
Study design
This FDA-CVM guided Pilot study to determine the safety, feasibility and preliminary efficacy
of cNIs in eliminating or significantly reducing a diabetic dog’s need for insulin is being carried
out as detailed in Methods. Six dogs have been administered allogeneic cNIs. The dogs’ pretreat-
ment demographics and comorbidities are summarized in Tables 2 and 3. Two dogs are being
treated for hypertriglyceridemia (gemfibrozil, 150 mg BID, and dietary restriction) and have
been treated but are not yet in the intermediate term follow-up phase of the study, while four
have been treated with cNIs (VSH-01, VSH-02, WSU-01 and WSU-02) and have been followed
for more than 6 months. VSH-01 was a 9 year old (at dosing), male, 12 kg French bulldog who
had been on insulin for approximately 2.5 years at the time of dosing. VSH-02 was a 7 year old,
hypothyroid, male, 7 kg Bichon mix who had been diabetic for approximately 6 months at the
time of dosing. WSU-01 was a 2 year old, 11 kg, female American Eskimo dog who had been on
insulin for approximately 9 months prior to treatment. WSU-02 was a 1 year old, 7 kg Chihua-
hua mix who had been on insulin for approximately 6 months prior to dosing.

Therapeutic doses of cNIs for all treated dogs were prepared, release-tested, packaged and
administered as described in Methods. All cells and final products met the release criteria listed
in Table 4. Prior to administration, cNIs were characterized by rtPCR for gene expression of
INS, GCG, SST, PPY, PDX-1, NKX6-1, VEGFA, and CXCL12. As shown in Fig 1, while PDX-
1 was no longer detectible in cNIs given to any dog, cNIs used for treatment transcribed islet
hormone genes for INS, GCG, SST and PPY albeit at significantly reduced levels compared to
P0 cultured islet cells. cNIs also expressed genes associated with ASCs cytoprotective, angio-
genic and immune modulatory activities [31–36] (Fig 1).

Intermediate term blood glucose levels and insulin requirements
As shown in Fig 2, blood glucose concentrations and insulin requirements for VSH-01, VSH-
02, and WSU-02 were significantly reduced (P < 0.05) ≥ 6 months post treatment compared
to baseline. Although WSU-01’s mean monthly blood glucose concentrations 12 months post
treatment were also significantly reduced compared to those at baseline (P = 0.0015), her daily
insulin needs remained unchanged (Fig 2). With the exception of WSU-01, all treated dogs
currently show both a sustained reduction in serum glucose concentrations and insulin doses.
WSU-01 showed continued reduction in serum glucose concentrations for her entire 12
month follow-up period, but only demonstrated a 20% reduction in insulin dose over 6
months post-treatment. After 7 months, her needed insulin dose rebounded to her pretreat-
ment levels and remains there now (see Fig 2).
Markers of intermediate-term glucose control

With the exception of VSH-02, all dogs' fructosamine levels were in the 200–400 μmol/L range both prior to and post-treatment, indicating consistent and good control of glucose levels on the parts of all owners. For VSH-02, pretreatment fructosamine was 439 μmol/L, and deceased post treatment to 285 μmol/L, which is within normal range. VSH-01’s fructosamine levels also decreased post-treatment to 297 μmol/L (within normal range). While HbA1c levels were called for in the protocol, they have been inconsistently recorded. However, VSH-02’s HbA1c decreased from 12.1 pre-treatment to 6.8% post-treatment.

Type of diabetes

As part of the study, serum from dogs was obtained prior to and after cNI dosing, and tested by FACS for antibodies to the administered cells, using pre-dosing serum and isotypes as negative controls. Pre-treatment testing of sera served not only the purpose of giving a baseline level of anti-ASC or anti-IC antibodies to compare to post-treatment levels, but also as an
indication of whether the dogs’ diabetes was auto-immune in nature, as indicated by the presence of anti-IC antibodies prior to treatment. By this criterion, three of the four tested dogs, VSH-02, WSU-01 and WSU-02, appear to have autoimmune diabetes (see Fig 3A and 3B), while VSH-01 may have an “insulin resistant” form of insulin-dependent DM.

Sera were similarly tested for the presence of antibodies to two common human autoimmune antigens that have been associated with canine T1DM, IA2 and GAD 65 [16,17]. Only pretreatment serum from WSU-01 showed reactivity to IA2. No other sera showed the presence of antibodies to either (Fig 3C).

Neither auto- nor allo-immune rejection is observed

Even though at least 3 of the treated dogs (VSH-02, WSU-01 and WSU-02) appear to have autoimmune diabetes (Type 1) as indicated by the presence of auto-anti-islet cell IgG in their sera (see Fig 3), and even though the cNIs used to treat them came from unrelated donors, none of the dogs appear to have rejected the cNIs as indicated by the following. First, responsive dogs show continued improved blood glucose concentrations and lowered insulin requirements (see Fig 2). Second, no allo-rejection antibodies to the cNIs are found in the treated dogs’ sera after implantation (Fig 3).
cNI therapy appears to be safe and well tolerated in dogs

In addition to regular blood glucose and weight monitoring, dogs enrolled in this study are being, and will continue to be, followed closely over the entire protocol-designated 3 year follow-up period with physical examinations and laboratory tests in order to detect signs of adverse events or changes in end organ damage in association with Neo-Islet therapy (see S2 Table).

Despite the fact that several of the currently studied dogs are of advanced age and have multiple comorbidities (see Tables 2 and 3), no adverse events attributable to the cNI therapy have been observed to date. Specifically, none of the 6 treated dogs have developed adverse events such as oncogenic transformation of transplanted cells, hematological changes, deterioration
in organ function, failure to thrive, etc. While at this point in the study we cannot rule out with certainty the possibility that adverse events can eventually occur, data in the nearly 2 years since the first dogs were treated would indicate that cNIs are safe and well tolerated.

Discussion

Intermediate term results from the current study thus far demonstrate that allogeneic cNI therapy, as currently dosed, (i) is effective in improving glycemic control while durably reducing insulin doses; (ii) it does so without eliciting an immune response, even in dogs with autoimmune diabetes; and (iii) is feasible and safe. The observed decrease in post-treatment compared to pre-treatment levels of anti-IC antibodies in two dogs (Fig 3A) may reflect the known inhibitory actions of ASCs on B cells [37]. However, this potentially significant effect must be confirmed in additional studies. While the documented reduction in total insulin requirement occurs only gradually as transplanted ICs, we postulate, re-differentiate, as was demonstrated in our previous publication [21] and in S1 Fig, into insulin producing cells, this response does taper off subsequently. However and importantly, the insulin dose does not, in most cases, increase again (Fig 2) as is frequently seen in failing, traditional intrahepatic islet cell transplants [38]. Significantly, we previously demonstrated in cNI treated, euglycemic, STZ-diabetic NOD/SCID mice, intraperitoneal glucose tolerance tests were of normal pattern compared to controls, and exclusively canine insulin was released [21]. Further, we show here (see S1 Fig) that cNI retrieved from euglycemic, STZ-diabetic, cNI treated NOD-SCID mice 9 weeks post-treatment secrete significantly increased quantities of insulin in response to glucose. These data clearly demonstrated that in this xenogeneic diabetic mouse model, cNIs redifferentiate in vivo into insulin producing cells [21]. In the present study, we cannot rule out the possibility that adherence to the protocol itself may contribute to the dogs' improved glycemic control. However, the fact that this is accompanied by a decrease in the overall need for exogenous insulin long term argues that the cNIs are contributing needed insulin. Although we have not conducted studies on the engrafted cNIs in these pet dogs, we postulate that the mechanism of action here is the same as was seen in the mice: that the cNIs redifferentiate in vivo to provide insulin in these diabetic dogs.

The data so far indicate that the allogeneic cNI grafts are stable and functioning long term, and are not being rejected, which directly demonstrates that this novel form of therapy does not require the life-long use of potentially toxic antirejection drugs. In other words, the allogeneic ASC component of the administered cNIs appears to provide through its immune-modulating activities [37] both robust auto- and allo-immune isolation of the cells that make up cNIs, and this without the need for often fail-prone encapsulation devices. For example, the use of such a subcutaneously implanted encapsulation device in a clinical trial has proved problematic, as it elicited an inflammatory fibrotic, foreign body type response that resulted in the death of the encapsulated insulin producing cells and thus failure so far of this mode of T1DM therapy [39].

Since the treated dogs are pets and the study is ongoing, the exact engraftment site of the i. p. administered cNIs has not been histologically confirmed, although we believe that the main engraftment site is the omentum as we clearly demonstrated in our mouse studies that also used cNIs [21]. Late post treatment glucose tolerance tests with simultaneous monitoring of canine insulin and C-Peptide release will be conducted in all study dogs.

There are several possible explanations for the incomplete normalization of blood glucose concentrations and failure to achieve complete insulin independence, contrary to what was found in mice treated with cNIs [21]. Incomplete responses may be related to an inadequate cNI dose, the potential need for a second dose, as is routinely done in human islet transplants [38] and as we demonstrated to be effective in incompletely controlled diabetic mice.
In addition, the need to keep the dog post cNI infusion for at least 24 hrs either in a prone or supine position may be important since both of these positions facilitate the omental engraftment of administered cNIs, while the assumption of an upright position will lead to the translocation of the transplants to the dog’s pelvis, a location that prevents their engraftment in the omentum and failure to function as intended [40]. The current technology exploits the omentum’s ability to both release cells and to take up cell aggregates such as cNIs via its milky spots, combined with its excellent arterial blood supply for oxygenation of and glucose sensing by engrafted cNIs. Importantly, the omentum’s venous drainage facilitates the physiological delivery of secreted insulin and other islet hormones directly into the portal system of the liver, i.e., a route that is identical to that of the pancreatic veins. Since the liver inactivates up to 50% of received insulin, the post-hepatic concentrations of insulin that other insulin-sensitive tissues are exposed to is significantly lower than those insulin levels that are generated by the s.c. injection of insulin that, particularly in higher doses, may have adverse systemic effects [41–43].

Finally, the ability to generate potentially more than 80 therapeutic cNI doses from a single cadaveric pancreas and ASC donor will significantly improve the availability of this therapy for diabetic dogs and thus assist their owners with the care of their pets. Once the therapy has been fully optimized to durably make diabetic dogs insulin independent, the cost savings over time are predicted to be significant.

In conclusion, completion of the current study with the remaining dogs will include permitted protocol modifications that we expect to augment the therapeutic efficacy of the so far utilized cNI treatment protocol. Nevertheless, we posit that the observations presented herein provide further evidence in support of our hypothesis and previously published work that NIs when given i. p. engraft in the omentum where they redifferentiate and create a new endocrine pancreas that leads to the establishment of euglycemia and insulin-independence [21]. The proof of principle, i.e., the demonstration that this NI therapy is also effective in a second, larger diabetic mammal, the dog, is definitively significant as this will further strengthen the justification for the currently planned conduct of a scientifically based clinical trial in human study subjects with T1DM.

**Supporting information**

S1 Table. PCR reagents used and their sources.

(SDOCX)

S2 Table. Follow-up testing schedule.

(SDOCX)

S1 Fig. Glucose Stimulated Insulin Secretion (GSIS) of cNIs before and after implantation in mice. GSIS per cNI of freshly formed cNIs vs. cNIs retrieved from euglycemic, STZ-diabetic, cNI-treated NOD-SCID mice 9 weeks post cNI administration. *, P < 0.05 compared to 5 mM glucose; **, P < 0.01 compared to pre-administration. These animals data were from those reported in [21].

(STIF)

S1 File. Methods for GSIS in freshly prepared cNIs vs. retrieved cNIs.

(SDOCX)

**Acknowledgments**

We thank Valorie Wiss at Washington State University for her excellent work as study coordinator. Some of the here-presented data were shown in poster format, and in oral presentations at the 78th and 79th American Diabetes Association Annual Sessions.
Author Contributions

Conceptualization: Anna Gooch, Christof Westenfelder.
Formal analysis: Anna Gooch, Christof Westenfelder.
Investigation: Ping Zhang, Zhuma Hu, Natasha Loy Son, Nicole Avila, Julie Fischer, Gregory Roberts, Rance Sellon.
Project administration: Anna Gooch, Christof Westenfelder.
Resources: Julie Fischer, Rance Sellon.
Supervision: Anna Gooch, Julie Fischer, Rance Sellon, Christof Westenfelder.
Visualization: Christof Westenfelder.
Writing – original draft: Anna Gooch, Christof Westenfelder.

References

1. Fall T, Hamlin HH, Hedhammar A, Kämpe O, Egenvall A. Diabetes mellitus in a population of 180,000 insured dogs: incidence, survival, and breed distribution. J Vet Intern Med. 2007; 21: 1209–1216. https://doi.org/10.1892/07-021.1 PMID: 18196728
2. Ahlgren KM, Fall T, Landegren N, Grimmelius L, von Euler H, Sundberg K, et al. Lack of evidence for a role of islet autoimmunity in the aetiology of canine diabetes mellitus. PLoS One. 2014; 9: e105473. https://doi.org/10.1371/journal.pone.0105473 PMID: 25153886
3. Gupta L, Glickman L, Glickman N. Time trends and risk factors for diabetes mellitus in dogs: Analysis of Veterinary Medical Data Base records (1970–1999). Vet J. 2003; 165: 240–247. https://doi.org/10.1016/S1090-0233(02)00242-3 PMID: 12672370
4. Adin CA, Gilor C. The Diabetic Dog as a Translational Model for Human Islet Transplantation. Yale J Biol Med. 2017; 90: 509–515. PMID: 28955189
5. Gilor C, Niessen SJM, Furrow E, DiBartola SP. What’s in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters. J Vet Intern Med. 2016; 30: 927–40. https://doi.org/10.1111/jvim.14357 PMID: 27461721
6. Morgan MJ, Vite CH, Radhakrishnan A, Hess RS. Clinical peripheral neuropathy associated with diabetes mellitus in 3 dogs. Can Vet J = La Rev Vet Can. 2008; 49: 583–6.
7. Vrabelova D, Adin C, Gilor C, Rajab A. Pancreatic Islet Transplantation: From Dogs to Humans and Back Again. Vet Surg. 2014; 43: 631–641. https://doi.org/10.1111/1532-950X.12224 x PMID: 24909456
8. Abalovich AG, Bacqué MC, Grana D, Milei J. Pig Pancreatic Islet Transplantation Into Spontaneously Diabetic Dogs. Transplant Proc. 2009; 41: 328–330. https://doi.org/10.1016/j.transproceed.2008.08.159 PMID: 19249548
9. Alejandro R, Latif Z, Polonsky KS, Shienvold FL, Civantos F, Mint DH. Natural history of multiple intrahepatic canine islet allotransplants during and following administration of cyclosporine. Transplantation. 1988; 45: 1036–1044. https://doi.org/10.1097/00007890-198806000-00008 PMID: 3132761
10. Shields EJ, Lam CJ, Cox AR, Rankin MM, Van Winkle TJ, Hess RS, et al. Extreme Beta-Cell Deficiency in Pancreata of Dogs with Canine Diabetes. PLoS One. 2015; 10: e0129809. https://doi.org/10.1371/journal.pone.0129809 PMID: 26057531
11. O’Kell AL, Wasserfall C, Catchpole B, Davison LJ, Hess RS, Kushner JA, et al. Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked? Diabetes. 2017; 66: 1443–1452. https://doi.org/10.2337/db16-1515 PMID: 28533295
12. Short AD, Catchpole B, Kennedy LJ, Barnes A, Fretwell N, Jones C, et al. Analysis of candidate susceptibility genes in canine diabetes. J Hered. 2007; 98: 518–25. https://doi.org/10.1093/jhered/esm048 PMID: 17611256
13. Fall T, Johansson Kreuger S, Juberget A˚ , Bergströ m A˚ , Hedhammar A˚ . Gestational diabetes mellitus in 13 dogs. J Vet Intern Med. 2008; 22: 1296–1300. https://doi.org/10.1111/j.1939-1676.2008.0199.x PMID: 18976285
31. Chen T, Yuan J, Duncanson S, Hibert ML, Kodish BC, Mylvaganam G, et al. Alginate encapsulation of beta cells with engineered microspheres: A biosynthetic platform for the treatment of diabetes. PLoS ONE. 2010; 5(8): e12292. PMID: 20729381

32. McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol. 2005; 177: 8053–64. PMID: 15111547
33. Tonne JM, Sakuma T, Deeds MC, Munoz-Gomez M, Barry Ma, Kudva YC, et al. Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy. Dis Model Mech. 2013; https://doi.org/10.1242/dmm.012591 PMID: 23828045

34. Yan X, Cai S, Xiong X, Sun W, Dai X, Chen S, et al. Chemokine receptor CXCR7 mediates human endothelial progenitor cells survival, angiogenesis, but not proliferation. J Cell Biochem. 2012; 113: 1437–1446. https://doi.org/10.1002/jcb.24015 PMID: 22173725

35. Tögel F, Zhang P, Hu Z, Westenfelder C. VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J Cell Mol Med. 2009; 13: 2109–2114. https://doi.org/10.1111/j.1582-4934.2008.00641.x PMID: 19397783

36. Sakata N, Chan NK, Chrisler J, Obenaus A, Hathout E. Bone marrow cells produce nerve growth factor and promote angiogenesis around transplanted islets. Bone. 2010; 16: 1215–1220. https://doi.org/10.3748/wjg.v16.i10.1215 PMID: 20222164

37. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med. Elsevier Ltd; 2012; 18: 128–34. https://doi.org/10.1016/j.molmed.2011.10.004 PMID: 22118960

38. Lablanche S, Vantyghem M-C, Kessler L, Wojtyszyn A, Borot S, Thivolet C, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018; 6: 527–537. https://doi.org/10.1016/S2213-8587(18)30078-0 PMID: 29776895

39. Dolgin E. Encapsulate this. Nat Publ Gr. Nature Publishing Group; 2014; 20: 9–11. https://doi.org/10.1038/nm0114-9 PMID: 24398953

40. de Groot M, Schuurs TA, van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. J Surg Res. 2012; 121: 128–34. https://doi.org/10.1016/j.jss.2012.02.018 PMID: 22118960

41. Gregory JM, Kraft G, Scott MF, Neal DW, Farmer B, Smith MS, et al. Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes. Diabetes. 2015; 64: 3439–3451. https://doi.org/10.2337/db15-0071 PMID: 26085570

42. Perksen N, Grefte T, Greisen J, Mengel A, Juhl C, Veldhuis JD, et al. Human insulin release processes measured by intraportal sampling. Am J Physiol Endocrinol Metab. 2002; 282: E695–702. https://doi.org/10.1152/ajpendo.00516.2000 PMID: 11832375

43. Gregory JM, Smith TJ, Slaughter JC, Mason HR, Hughey CC, Smith MS, et al. Iatrogenic Hyperinsulinaemia, Not Hyperglycaemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Diabetes. 2019; 68: 1565–1576. https://doi.org/10.2337/db19-0324 PMID: 31092478